Novo Nordisk's Pipeline Momentum Collides With a Market Still Fixated on 2030

Novo Nordisk shares dropped 10% over seven days as its 2026-2030 revenue target matched industry averages, despite two EMA wins and strong CagriSema data.

Novo Nordisk spent the past week proving it can do two things at once: win regulatory favor in Europe and post competitive clinical data. What it could not do was convince shareholders that any of it offsets the slow-burning problem of semaglutide's patent expiry.

The Danish drugmaker's shares closed Wednesday at EUR 33.94, capping a seven-day stretch in which the stock shed 10.0 percent. At one point during the company's capital markets day in London, the decline reached 9 percent as management fielded pointed questions from investors about pricing power and acquisition strategy. The trigger: a revenue target for 2026 through 2030 that lands squarely in line with the industry average — hardly the kind of ambition that reassures a market already pricing in a post-semaglutide world.

Two EMA Nods in Two Days

While the capital markets day dominated headlines, Novo Nordisk was quietly stacking up regulatory wins on the continent. On September 17, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of FREHEMGO for preventive treatment of hemophilia A in adults and children. A European launch is planned for the fourth quarter of 2026.

The following day brought a second endorsement: Sogroya, the company's growth hormone, received a positive opinion for treating children with idiopathic short stature. Should the European Commission grant approval, it would become the first authorized therapy for this indication in the EU.

Both recommendations feed directly into CEO Mike Doustdar's stated goal of broadening the portfolio well beyond the GLP-1 franchise that built the company.

Clinical Data Cuts Both Ways

The pipeline narrative got a boost from fresh Phase 3 results. In the REIMAGINE 5 trial, the combination therapy CagriSema produced 12.4 percent weight loss after 60 weeks in patients with type 2 diabetes, outpacing tirzepatide's 9.1 percent. On HbA1c reduction, the pairing of cagrilintide and semaglutide proved non-inferior to its rival.

Separately, the REDEFINE 9 obesity study showed CagriSema achieving 21.0 percent weight loss after 68 weeks, compared with 2.0 percent for placebo. A US FDA decision on CagriSema for weight management is expected in the fourth quarter of 2026.

If Novo Nordisk can convert this pipeline on schedule, the company's risk-adjusted pipeline revenue target of more than DKK 150 billion by 2035 comes into view. Management has also signaled plans to expand oral formulation capacity enough to treat ten times as many people with obesity — a volume play that only works if margins hold.

The Pricing Question Nobody Can Answer

That "if" is where the bull case gets shaky. The central tension running through the capital markets day was whether Novo Nordisk can turn enormous GLP-1 volume growth into durable earnings as patents on existing blockbusters edge closer to expiry. Analysts have flagged muted medium-term growth and the looming loss of semaglutide exclusivity after 2030 as structural headwinds.

The bear scenario is straightforward: if GLP-1 price erosion accelerates faster than production capacity expands, margins face sustained pressure. Add to that the regulatory risk still attached to CagriSema, which remains under review and has yet to clear the FDA without issue. Delays or unexpected safety signals would deal a serious blow to medium-term growth targets.

There is also the question of external partnerships. Novo Nordisk's return of rights to TransCon technologies to Ascendis Pharma serves as a reminder that outside research approaches do not always translate smoothly into the company's own commercialization engine. And if the company stays cautious on acquisitions while competitors move aggressively to capture market share, a gradual slowdown becomes harder to avoid.

The company has been buying back its own stock as a partial offset. Through September 18, Novo Nordisk had repurchased B-shares worth more than DKK 9.6 billion since February. Year-to-date, the stock is down 23 percent.

A EUR 1.165 Billion Bet on Delivery Technology

One recent move illustrates how Novo Nordisk is trying to buy time — and capability. On Thursday, the company secured a worldwide exclusive license to Nanexa's PharmaShell technology for up to five development programs targeting obesity, type 2 diabetes, and cardiometabolic disease. The deal carries upfront and milestone payments of up to EUR 1.165 billion, plus low single-digit royalties.

The technology could extend dosing intervals, a meaningful differentiator in a market where convenience increasingly drives patient choice. It also complements the company's existing pipeline: more than five blockbuster medicines are slated for launch by 2030, though Novo Nordisk has been careful to stress that these ambitions do not constitute financial guidance.

Singapore's regulator added another data point on Wednesday, approving Wegovy as the first therapy for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis.

What to Watch

Near-term catalysts could shift the narrative. At the EASD congress in Milan from September 28 to October 2, Novo Nordisk will present 44 abstracts, including new data on the Wegovy pill and CagriSema. The FDA's decision on CagriSema for weight control follows in Q4 2026, and on November 4, 2026, the company reports results for the first nine months of the year.

Until then, the stock's stabilization potential rests on whether the market believes Novo Nordisk can deliver on its growth ambitions without drastic margin erosion. Should the perception take hold that pricing power in the core business is eroding for good, the recent weakness may prove to be more than a pause.